These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

40 related articles for article (PubMed ID: 36191884)

  • 1. Leukemic presentation and progressive genomic alterations of MCD/C5 diffuse large B-cell lymphoma (DLBCL).
    Kim PM; Nejati R; Lu P; Thakkar D; Mackrides N; Dupoux V; Nakhoda S; Baldwin DA; Pei J; Dave SS; Wang YL; Wasik MA
    Cold Spring Harb Mol Case Stud; 2023 Dec; 9(4):. PubMed ID: 37730436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Prevalence of MYD88 L265P and TNFAIP3 Mutations and Their Correlations with Clinico-Hematological Profile in Egyptian Patients with Diffuse Large B Cell Lymphoma.
    Elbaz O; Shaat RM; Abd El Ghaffar HA; Shamaa S; Abdel-Masseih HM; Anber N; Mortada MI
    Asian Pac J Cancer Prev; 2023 Jul; 24(7):2485-2491. PubMed ID: 37505783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. B-cell receptor signaling in diffuse large B-cell lymphoma.
    Young RM; Shaffer AL; Phelan JD; Staudt LM
    Semin Hematol; 2015 Apr; 52(2):77-85. PubMed ID: 25805587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sinonasal DLBCL: molecular profiling identifies subtypes with distinctive prognosis and targetable genetic features.
    Eriksen PRG; de Groot F; Clasen-Linde E; de Nully Brown P; de Groen R; Melchior LC; Maier AD; Minderman M; Vermaat JSP; von Buchwald C; Pals ST; Heegaard S
    Blood Adv; 2024 Apr; 8(8):1946-1957. PubMed ID: 38324724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SPIB and BATF provide alternate determinants of IRF4 occupancy in diffuse large B-cell lymphoma linked to disease heterogeneity.
    Care MA; Cocco M; Laye JP; Barnes N; Huang Y; Wang M; Barrans S; Du M; Jack A; Westhead DR; Doody GM; Tooze RM
    Nucleic Acids Res; 2014 Jul; 42(12):7591-610. PubMed ID: 24875472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of KT-413, a Targeted Protein Degrader of IRAK4 and IMiD Substrates Targeting MYD88 Mutant Diffuse Large B-Cell Lymphoma.
    Weiss MM; Zheng X; Ji N; Browne CM; Campbell V; Chen D; Enerson B; Fei X; Huang X; Klaus CR; Li H; Mayo M; McDonald AA; Paul A; Rong H; Sharma K; Shi Y; Slavin A; Walther DM; Yuan K; Zhang Y; Zhu X; Kelleher J; Walker D; Mainolfi N
    J Med Chem; 2024 Jul; 67(13):10548-10566. PubMed ID: 38920289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SYK is activated by mutated MYD88 and drives pro-survival signaling in MYD88 driven B-cell lymphomas.
    Munshi M; Liu X; Chen JG; Xu L; Tsakmaklis N; Demos MG; Kofides A; Guerrera ML; Jimenez C; Chan GG; Hunter ZR; Palomba ML; Argyropoulos KV; Meid K; Keezer A; Gustine J; Dubeau T; Castillo JJ; Patterson CJ; Wang J; Buhrlage SJ; Gray NS; Treon SP; Yang G
    Blood Cancer J; 2020 Jan; 10(1):12. PubMed ID: 32005797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response to Bruton's tyrosine kinase inhibitors in aggressive lymphomas linked to chronic selective autophagy.
    Phelan JD; Scheich S; Choi J; Wright GW; Häupl B; Young RM; Rieke SA; Pape M; Ji Y; Urlaub H; Bolomsky A; Doebele C; Zindel A; Wotapek T; Kasbekar M; Collinge B; Huang DW; Coulibaly ZA; Morris VM; Zhuang X; Enssle JC; Yu X; Xu W; Yang Y; Zhao H; Wang Z; Tran AD; Shoemaker CJ; Shevchenko G; Hodson DJ; Shaffer AL; Staudt LM; Oellerich T
    Cancer Cell; 2024 Feb; 42(2):238-252.e9. PubMed ID: 38215749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antigen-independent, autonomous B cell receptor signaling drives activated B cell DLBCL.
    Eken JA; Koning MT; Kupcova K; Sepúlveda Yáñez JH; de Groen RAL; Quinten E; Janssen J; van Bergen CAM; Vermaat JSP; Cleven A; Navarrete MA; Ylstra B; de Jong D; Havranek O; Jumaa H; Veelken H
    J Exp Med; 2024 May; 221(5):. PubMed ID: 38512136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unraveling the enigma of B cells in diffuse large B-cell lymphoma: unveiling cancer stem cell-like B cell subpopulation at single-cell resolution.
    Liu F; Zheng J; Yang G; Pan L; Xie Y; Chen S; Tuo J; Su J; Ou X; Liu R
    Front Immunol; 2023; 14():1310292. PubMed ID: 38149239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An inducible Cd79b mutation confers ibrutinib sensitivity in mouse models of Myd88-driven diffuse large B-cell lymphoma.
    Flümann R; Hansen J; Meinel J; Pfeiffer P; Goldfarb Wittkopf H; Lütz A; Wirtz J; Möllmann M; Zhou T; Tabatabai A; Lohmann T; Jauch M; Beleggia F; Pelzer B; Ullrich F; Höfmann S; Arora A; Persigehl T; Büttner R; von Tresckow B; Klein S; Jachimowicz RD; Reinhardt HC; Knittel G
    Blood Adv; 2024 Mar; 8(5):1063-1074. PubMed ID: 38060829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T Cells Spatially Regulate B Cell Receptor Signaling in Lymphomas through H3K9me3 Modifications.
    Britto LS; Balasubramani D; Desai S; Phillips P; Trehan N; Cesarman E; Koff JL; Singh A
    Adv Healthc Mater; 2024 Jun; ():e2401192. PubMed ID: 38837879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simplified algorithm for genetic subtyping in diffuse large B-cell lymphoma.
    Shen R; Fu D; Dong L; Zhang MC; Shi Q; Shi ZY; Cheng S; Wang L; Xu PP; Zhao WL
    Signal Transduct Target Ther; 2023 Apr; 8(1):145. PubMed ID: 37032379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An early regulatory mechanism of hyperinflammation by restricting monocyte contribution.
    Akiyama M; Kanayama M; Umezawa Y; Nagao T; Izumi Y; Yamamoto M; Ohteki T
    Front Immunol; 2024; 15():1398153. PubMed ID: 39040105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Establishment and characterization of a new activated B-cell-like DLBCL cell line, TMD12.
    Nagao T; Yoshifuji K; Sadato D; Motomura Y; Saito M; Yamamoto K; Yamamoto K; Nogami A
    Exp Hematol; 2022 Dec; 116():37-49. PubMed ID: 36191884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncogenically active MYD88 mutations in human lymphoma.
    Ngo VN; Young RM; Schmitz R; Jhavar S; Xiao W; Lim KH; Kohlhammer H; Xu W; Yang Y; Zhao H; Shaffer AL; Romesser P; Wright G; Powell J; Rosenwald A; Muller-Hermelink HK; Ott G; Gascoyne RD; Connors JM; Rimsza LM; Campo E; Jaffe ES; Delabie J; Smeland EB; Fisher RI; Braziel RM; Tubbs RR; Cook JR; Weisenburger DD; Chan WC; Staudt LM
    Nature; 2011 Feb; 470(7332):115-9. PubMed ID: 21179087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. B-cell-specific conditional expression of Myd88p.L252P leads to the development of diffuse large B-cell lymphoma in mice.
    Knittel G; Liedgens P; Korovkina D; Seeger JM; Al-Baldawi Y; Al-Maarri M; Fritz C; Vlantis K; Bezhanova S; Scheel AH; Wolz OO; Reimann M; Möller P; López C; Schlesner M; Lohneis P; Weber AN; Trümper L; ; Staudt LM; Ortmann M; Pasparakis M; Siebert R; Schmitt CA; Klatt AR; Wunderlich FT; Schäfer SC; Persigehl T; Montesinos-Rongen M; Odenthal M; Büttner R; Frenzel LP; Kashkar H; Reinhardt HC
    Blood; 2016 Jun; 127(22):2732-41. PubMed ID: 27048211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CARMA1- and MyD88-dependent activation of Jun/ATF-type AP-1 complexes is a hallmark of ABC diffuse large B-cell lymphomas.
    Juilland M; Gonzalez M; Erdmann T; Banz Y; Jevnikar Z; Hailfinger S; Tzankov A; Grau M; Lenz G; Novak U; Thome M
    Blood; 2016 Apr; 127(14):1780-9. PubMed ID: 26747248
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.